Sosei Group Corporation (TYO: 4565) has dosed the first patient in an expansion cohort of the Phase 1b segment of its Phase 1 study in advanced solid tumours being conducted in collaboration with AstraZeneca (LON: AZN), the company announced on Thursday.
The two companies are also expected to start a new clinical study including AZD4635 to investigate novel combination therapies in EGFRm non-small cell lung cancer in the first quarter of 2018.
AZD4635 is a potent and selective, orally available, small molecule adenosine A2A receptor (A2AR) antagonist that was discovered by Sosei's subsidiary, Heptares Therapeutics. It was licensed to AstraZeneca in 2015.
The Phase 1 trial is investigating AZD4635 in patients with advanced solid malignancies. The primary objective is to determine the maximum tolerated dose of AZD4635 as a monotherapy, as well as in combination with AstraZeneca's anti-PD-L1 antibody durvalumab.
Sosei expects the Phase 1b expansion cohort in advanced solid tumours, which is sponsored by AstraZeneca, to complete in the second half of 2019.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review